Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/16/2017 08/17/2017 08/18/2017 08/21/2017 08/22/2017 Date
2.77(c) 2.8(c) 2.77(c) 2.72(c) 2.72 Last
355 952 335 719 334 344 379 693 549 131 Volume
-3.15% +1.08% -1.07% -1.81% 0.00% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -19,9 M
Net income 2017 -19,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 9,87 M
EBIT 2018 -22,3 M
Net income 2018 -22,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 23,3x
Capitalization 230 M
More Financials
Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company.It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder.The... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Surperformance© ratings of Catalyst Pharmaceuticals I
Trading Rating : Investor Rating : -
More Ratings
Latest news on CATALYST PHARMACEUTICALS I
08/10 CATALYST PHARMACEUTICALS INC : Investor Network: Catalyst Pharmaceuticals, Inc. ..
08/09 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Financial Statements a..
08/09 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
08/09 CATALYST PHARMACEUTICALS : Announces Second Quarter 2017 Financial Results and P..
08/09 CATALYST PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
08/01 Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference ..
07/12 CATALYST PHARMACEUTICALS, INC. : Other Events (form 8-K)
06/26 Catalyst Pharmaceuticals Joins Russell 3000 Index
06/01 Catalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conferen..
05/26 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Departure of Directors..
More news
Sector news : Bio Therapeutic Drugs
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Bio Therapeutic Drugs
Latest Tweets
08/14Catalyst Pharmaceuticals, Inc. to Post Q4 2017 Earnings of -$0.05 Per Share, .. 
08/10Roth Capital Analysts Give Catalyst Pharmaceuticals, Inc. $CPRX a $5.00 Price.. 
08/10Catalyst Pharmaceuticals given $5.00 PT by Roth Capital. buy rating.  
08/10Catalyst Pharmaceuticals Announces Second Quarter 2017 Financial Results and .. 
08/09Catalyst Pharmaceutical beats by $0.01  
More tweets
Qtime:16
News from SeekingAlpha
08/10 Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2017 Resul..
08/09 Catalyst Pharmaceutical beats by $0.01
06/07 Catalyst Pharmaceuticals (CPRX) Presents At Jefferies 2017 Global Healthcare ..
05/11 Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2017 Resul..
05/10 Catalyst Pharmaceutical EPS in-line
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Technical analysis trends CATALYST PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 5,44 $
Spread / Average Target 100%
EPS Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President & Chief Executive Officer
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer & Head-Regulatory Affairs
Philip H. Coelho Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICALS INC159.05%230
AMGEN14.42%122 067
CELGENE CORPORATION10.28%99 867
GILEAD SCIENCES0.70%94 170
REGENERON PHARMACEUTICALS27.48%50 145
VERTEX PHARMACEUTICALS101.07%37 346